Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

115.20EUR
3 Aug 2020
Change (% chg)

€-1.35 (-1.16%)
Prev Close
€116.55
Open
€116.80
Day's High
€117.60
Day's Low
€112.75
Volume
149,982
Avg. Vol
170,902
52-wk High
€146.30
52-wk Low
€65.25

Summary

Name Age Since Current Position

Marc Cluzel

59 2018 Independent Chairman of the Supervisory Board

Jean-Paul Kress

2019 Chief Executive Officer

Jens Holstein

2011 Chief Financial Officer, Member of the Management Board

David Trexler

2019 President - MorphoSys US Inc

Sarah Fakih

2019 Vice President and Head of Corporate Communications and Investor Relations

Malte Peters

2017 Chief Development Officer , Member of the Management Board

Roland Wandeler

2020 Chief Commercial Officer, Member of the Management Board

Sharon Curran

2019 Independent Member of the Supervisory Board

Wendy Johnson

2015 Independent Member of the Supervisory Board

Michael Brosnan

65 2018 Independent Member of the Supervisory Board

George Golumbeski

2018 Independent Member of the Supervisory Board

Krisja Vermeylen

2017 Independent Member of the Supervisory Board

Biographies

Name Description

Marc Cluzel

Dr. Marc Cluzel, M.D. Ph.D. serves as Independent Chairman of the Supervisory Board of MorphoSys AG since May 17, 2018. He has more than 20 years of knowledge and experience in Research & Development and product registration in the United States, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011 and serves also as Executive Vice President of Product Development at HUYA Bioscience International, LLC. Dr. Cluzel served as global head of Research and Development for Sanofi from 2007 to 2011, as Executive Vice President of Research and Development for Sanofi (Formerly Sanofi-Aventis SA) and before 2009 as its Senior Vice President of Science and Medical Affairs. He was also since 2002 Chairman and Chief Executive Officer of Sanofi-Synthelabo R&D France then Sanofi-Aventis R&D France. His career began in hospital medical care and gradually transitioned to research at Johns Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel holds both an MD degree and a Ph.D. degree from the Universite de Montpellier, France.

Jean-Paul Kress

Dr. Jean-Paul Kress, M.D., is appointed as Chief Executive Officer of the Company with effective from September 1, 2019. Dr. Jean-Paul Kress held many senior leadership positions in pharmaceutical and biotechnology firms. Prior to joining MorphoSys, Dr. Kress served as President and Chief Executive Officer at Syntimmune, now a subsidiary of Alexion Pharmaceuticals. Before, he acted as Executive Vice President and President, International, and Head of Global Therapeutic Operations at Biogen Inc., overseeing the company's rare and specialty disease teams. Previously, Dr. Kress was Senior Vice President, Head of North America at Sanofi Genzyme, where he was instrumental in launching several therapeutic products, including dupilumab, the first biologic agent approved in atopic dermatitis. Prior to this, he was President and Chief Executive Officer of Sanofi Pasteur MSD, a vaccines joint venture of Sanofi and Merck & Co. Dr. Kress also held leadership roles at Gilead, serving as Vice President, US Sales and Marketing, and Vice President, General Manager for France. He began his industry career with Eli Lilly in France and held commercial and business development roles in the US and Europe at Abbott (now AbbVie). Dr. Kress received an M.D.degree from Faculté Necker-Enfants Malades in Paris, and graduate andpost-graduate degrees in pharmacology and immunology from École Normale Supérieure in Paris.

Jens Holstein

Mr. Jens Holstein is Chief Financial Officer and Member of the Management Board at MorphoSys AG from May 1, 2011. He is responsible for accounting and controlling, corporate development, treasuryand technical operations including Information Technology (IT), and the corporate legal function. Prior to joining the Company he served as Regional CFO for Europe/Middle East and as Managing Director of Fresenius Kabi Deutschland GmbH. Over nearly 16 years at Fresenius Kabi Deutschland GmbH, he held a variety of financial and general management positions. Before that, he had spent several years in the consulting industry working in Frankfurt and London.

David Trexler

Sarah Fakih

Dr. Sarah Fakih has been Vice President and Head of Corporate Communications and Investor Relations of MorphoSys AG since April 1, 2019. She joined MorphoSys from Qiagen N.V., a global provider of sample and assay technologies for molecular diagnostics, academic research, the pharmaceutical industry and applied testing. She has held the position of Director Investor Relations from April 2018 at Qiagen N.V. in Hilden. She joined the Investor Relations Department in October 2015, having started as a scientist at Qiagen in 2009. She has a Ph.D. in Chemistry (Dr. rer. nat.) from the University of Muenster, held a Postdoctoral position at the King's College London, Department of Pharmacy, and was awarded a habilitation at the University of Goettingen, Department of Inorganic Chemistry. She had also been appointed to a full professorship for Coordination Chemistry / Bioinorganic Chemistry at the Ludwig-Maximilians-University of Munich in 2009 and has a Master of Business Administration (MBA) from the University of Wuerzburg in collaboration with the Florida Gulf Coast University, USA and Boston University, USA.

Malte Peters

Dr. Malte Peters is appointed as Chief Development Officer , Member of the Management Board of MorphoSys AG effectively from March 1, 2017. He served at Sandoz, where he serves as Global Head, Clinical Development Biopharmaceuticals. Dr. Peters built his career in early and late-stage clinical development over the last 18 years. Prior to his latest role at Sandoz, he spent 12 years in various managerial positions within Novartis focusing on management of clinical development projects in oncology. Before that, Dr. Peters served in positions as Medical Director at Micromet AG and as Head of Translational Research and Pharmacogenomics at Merck KGaA.

Roland Wandeler

Dr. Roland Wandeler Ph.D. has been appointed as Chief Commercial Officer, Member of the Management Board of the Company effective 5/5/2020. Mr. Roland Wandeler has more than 15 years of commercial leadership and general management experience in the pharmaceutical and biotechnology industry, with a strong track record of building and leading sizable affiliates and U.S. franchises across multiple therapeutic areas, including oncology and hematology. Prior to MorphoSys, Mr. Wandeler held positions of increasing responsibility at Amgen, Inc., including General Manager Germany in Munich and General Manager Spain & Portugal in Barcelona, before most recently serving as Corporate Vice President and General Manager of Amgen's US Bone Health and Cardiology Business Unit in Thousand Oaks, California. Mr. Wandeler initially joined Amgen in 2006 in strategic planning for its international business. Subsequent highlights include sales and business unit leadership roles in Germany at the time of several launches across therapeutic areas. Mr. Wandeler began his career at Boston Consulting Group (BCG) in Zurich, Switzerland and Los Angeles, California, where he was a core member of BCG's global Healthcare Practice as well as a Member of the Zurich and Los Angeles Management Teams. Dr. Wandeler holds a M.Sc. in Chemical Engineering and a Doctorate in Technical Sciences from ETH Zurich.

Sharon Curran

Ms. Sharon Curran serves as Independent Member of the Supervisory Board of the Company. Ms. Curran is a non-executive director in the life sciences and healthcare industries and brings extensive commercial and specialist pharmaceutical experience to the Company.

Wendy Johnson

Michael Brosnan

Mr. Michael Brosnan serves as Independent Member of the Supervisory Board of MorphoSys AG effective as of May 17, 2018. He has over 40 years of experience in finance, controlling and auditing. Since 2010, he has served as Chief Financial Officer of Fresenius Medical Care Management AG, Bad Homburg, Germany, a company with a dual listing in Germany (Frankfurt) and the United States (NYSE). Over the last 20 years, he has worked in various leadership and executive positions for Fresenius Medical Care in the United States and Germany. Prior to joining Fresenius Medical Care, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG. Mr. Brosnan holds a degree in business administration and accounting from Northeastern University, Boston, MA, USA.

George Golumbeski

Dr. George S. Golumbeski, Ph.D., serves as Independent Member of the Supervisory Board of MorphoSys AG effective as of May 17, 2018. He currently serves as Executive Vice President & Executive Advisor for Innovation at Celgene Corporation, Summit, NJ, USA. He will retire from this position on April 16, 2018. Over the last 27 years, he has held leadership roles in business and corporate development, partnering and M&A with global pharmaceutical and life science companies, including Celgene, Novartis, Elan Corporation (currently: Perrigo), and Schwarz Pharma (currently: UCB). Dr. Golumbeski obtained his doctorate in genetics from the University of Wisconsin in Madison, USA and holds a degree in biology from the University of Virginia, Charlottesville, USA. member of the supervisory board of: Aura Biosciences Inc., Cambridge, MA, USA (Chairman of the Board of Directors) Carrick Therapeutics Ltd., Dublin, Ireland (Chairman of the Board of Directors) Enanta Pharmaceuticals, Inc., Watertown, MA, USA (Member of the Board of Directors) KSQ Therapeutics, Inc., Cambridge, MA, USA (Member of the Board of Directors) Sage Therapeutics, Cambridge, MA, USA (Member of the Board of Directors) Shattuck Labs, Inc., Austin, TX, USA (Member of the Board of Directors) Verseau Therapeutics, Inc., Bedford, MA, USA (Chairman of the Board of Directors).

Krisja Vermeylen

Ms. Krisja Vermeylen serves as Independent Member of the Supervisory Board of the Company. member of the supervisory board of: Spencer Stuart, Belgium (Member of the Advisory Board).

Basic Compensation